Wednesday, Mar 19, 1997

Leader in Oncology to Head Genentech's Molecular Oncology Department

South San Francisco, Calif. -- March 19, 1997 --

Genentech today announced the appointment of Vishva M. Dixit, M.D. to director of the company's Molecular Oncology department.

Dr. Dixit, who has authored or co-authored approximately 80 scientific publications, is renowned for his biochemical research that helped elucidate critical components of the programmed cell death pathway. Over the past several years, programmed cell death has been demonstrated to play an important role in cancer as well as in a number of degenerative diseases. The ability to modulate this process could provide new strategies for the development of cancer therapeutics. Dr. Dixit's work in this area recently resulted in a shared second place position in the annual Science Watch poll, that ranks scientists who have produced the greatest number of highly cited papers over the last two years.

"Genentech is committed to a strong research discovery program in the area of oncology, and we are confident that Vishva Dixit will provide important leadership to our efforts in this area," said Dennis Henner, Ph.D., vice president of Research.

"I am very excited to be joining Genentech, which is a state-of-the-art research center committed to scientific excellence," said Dr. Dixit. "I look forward to the opportunity to continue my basic research, as well as translate that work into human therapeutics designed to address important medical needs."

Dr. Dixit is currently a professor of Pathology at the University of Michigan Medical School, Ann Arbor, Michigan, where he started as an assistant professor in 1986. He serves on the editorial boards of the Journal of Biological Chemistry, Laboratory Investigation, and the Journal of Clinical Investigation . He received his M.D. from the University of Nairobi, Kenya, in 1980. Following an internship at the Kenyatta National Hospital, Kenya, he moved to Washington University, St. Louis, Missouri, to pursue residency training in pathology and post-doctoral work in biochemistry.

Genentech is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. Eleven of the currently marketed biotechnology products stem from Genentech science, six of which Genentech markets directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #